<DOC>
	<DOCNO>NCT00689728</DOCNO>
	<brief_summary>The purpose study explore whether LY2127399 effective relieving sign symptom RA patient history inadequate response intolerance least 1 TNFα inhibitor therapy . Examples TNFα inhibitor therapy currently market include Enbrel® ( etanercept ) , Remicade® ( infliximab ) , Humira® ( adalimumab ) .</brief_summary>
	<brief_title>A Study Patients With Rheumatoid Arthritis Methotrexate ( MTX ) With Inadequate Response TNFα Inhibitor Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Have give write informed consent approval Women must risk become pregnant study participation Diagnosis Rheumatoid Arthritis Active Rheumatoid Arthritis Current , regular use Methotrexate , stable dose Have least 1 biologic TNFα inhibitor therapy either fail intolerant treatment Other criterion review study doctor Use exclude medication ( review study doctor ) Have medical finding , opinion study doctor , put patient unacceptable risk participation study Have recent ongoing infection , opinion study doctor put patient unacceptable risk participation Evidence tuberculosis Have systemic inflammatory condition RA , juvenile RA , seronegative spondyloarthropathy , Crohn 's disease , ulcerative colitis , psoriatic arthritis . Other criterion review study doctor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>